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Abstract: Human chorionic gonadotropin (hCG) is a hormone that specifically binds to luteinizing
hormone receptor (LHR) and exerts several roles, including the support of pregnancy and fetal
gonadal steroidogenesis. Since hCG is also expressed by some tumor types, like breast cancer, many
efforts have been made to study its role in neoplesia, with some studies showing a cancer-supportive
role and others showing a cancer-protective role. A critical examination of the literature highlighted
that the in vitro effect of hCG has been tested in the presence of fetal serum, which contains other
gonadotropins, in the culture medium. Thus, we hypothesized that the use of serum in the cell
culture medium might influence the cell response to the hCG treatment due to the presence of other
hormones. Thus, we analyzed the in vitro effect of highly purified hCG on cell proliferation and
the activation of the down-stream signal transduction pathway in three breast cancer cell lines,
particularly focusing on MCF7, cultured in serum-deprived conditions. Our data show that hCG
increases cell proliferation and activates the down-stream target Akt, together with a decrease of the
LHR mRNA expression level. Finally, we also tested the differentiation capacity of hCG on MCF7
cancer stem cells (CSCs) and show that it favors the proliferation and differentiation of these cells,
thus suggesting that hCG also renders cells more able to colonize and invade the organs.
Keywords: human chorionic gonadotropin (hCG); breast cancer cells; MCF7; cancer stem cells;
cancer proliferation
1. Introduction
Human chorionic gonadotropin (hCG) is a glycoprotein hormone that belongs to the
gonadotropin hormone family, which also includes luteinizing hormone (LH) and follicle-
stimulating hormone (FSH). hCG is a heterodimeric protein with two subunits: the alpha-
subunit that is identical to that of LH, FSH, and thyroid-stimulating hormone (TSH), and
the beta-subunit that is specific to hCG alone. These hormones bind to specific G protein-
coupled receptors (GPCRs): LH and hCG bind to luteinizing hormone receptor (LHR),
whereas FSH binds to follicle-stimulating hormone receptor (FSHR). LHR is principally
expressed in the ovary and testicular cells, and its activation is fundamental to activating
the hormone functions. hCG is mainly produced by the placenta during pregnancy, but
it is also expressed at lower levels in other tissues, including the testis, prostate, thymus,
skeletal muscles, and pituitary gland, by exerting an autoregulatory growth-promoting
role [1]. Its role in normal tissue seems to be mainly autoregulatory by favoring the
stimulation of cell growth [2]. Despite the molecular effect of hCG on fertility being a clinical
subject matter [3,4], its role in cancer development has not yet been completely assessed
and remains controversial, with some authors showing that hCG exerts anti-tumoral
effects by decreasing cell proliferation [5], and others showing that it acts as a pro-cancer
hormone [6,7]. In support of the protective role of hCG against breast cancer, in vitro studies
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demonstrated that hCG decreased cancer cell proliferation [8], and in vivo models showed
that hCG administration reduced the risk of carcinogen-induced breast cancer in rats,
together with the induction of apoptosis [9,10]. Instead, concerning the pro-tumorigenic
role of hCG, it has been shown that some tumors, including breast, bladder, and testicular
cancer [11,12], express this hormone at high levels, thus making it a potential tumor marker
and a tool to monitor disease progression [13]. An interesting study performed on breast
cancer patients showed that β-hCG mRNA was present in the blood of 80% of primary
breast cancers, whereas it was not expressed in negative controls, representing a potential
marker for the detection of metastatic breast cancer cells. Furthermore, transgenic mice
overexpressing β-hCG have been shown to develop multiple neoplasms, including breast
cancer, also showing that hCG can up-regulate Wnt7b and Wnt5b, thus contributing to
pregnancy-induced breast cancer in humans [14]. In vitro studies also showed that β-hCG
promotes cancer cell invasion in different types of tumors [15,16].
Another important element linked to the action of hCG is the expression level of
LHR, whose role as a pro- or anti-tumor agent is controversial as well. Indeed, LHR
expression has been reported to be associated with favorable tumor characteristics [17] and,
controversially, in another study it was reported to be increased in invasive breast cancer
cases in comparison to preinvasive specimens.
Since the effect and the role of hCG in cancer cells still remain unclear, we critically
examined different studies in which hCG has been tested in vitro and hypothesized that a
general common issue is the presence in the culture medium of fetal serum, the formulation
of which contains both LH and FSH. Among all the components of fetal serum, we suggest
that the presence of these two hormones might activate the same signal transduction
pathway as hCG, rendering it impossible to discern the real effect of hCG on the tested
cells. For this reason, the aim of this study was to test the effect of highly purified hCG
in breast cancer cell lines, particularly focusing on MCF7 cells, cultured without serum.
Furthermore, since Liao et al. showed that hCG stimulates cells to differentiate [8], we also
analyzed, in serum-deprived conditions, the effect of hCG on MCF7 cancer stem cell (CSC)
proliferation and differentiation.
2. Materials and Methods
This prospective observational study was approved by the Pediatric Fertility Lab
internal review board (09/2020).
2.1. Drugs and Chemicals
Highly purified human chorionic gonadotropin (hCG) extracted from pregnant women’s
urine was kindly provided by IBSA Italia (Lodi, Italy).
2.2. Cell Lines
To investigate the effect and the role of hCG in cancer cells, the following cell lines
were used: a pancreatic ductal adenocarcinoma cell line (PaCa44) and breast cancer cell
lines (MCF7, T47D, and MDA-MB-231). Due to its origin, the PaCa44 cell line does not
express LHR; thus, it was identified as control cell line. PaCa44 cells were grown in RPMI-
1640, whereas MCF7, T47D, and MDA-MB-231 cells were grown in DMEM-Glutamax,
both supplemented with 10% fetal bovine serum (FBS) (generally containing FSH and LH
at different concentrations depending on the lot, as reported by different manufacturers’
sheets) and 50 µg/mL gentamicin sulfate (all from Thermo Fisher Scientific, Waltham,
MA, USA), and maintained at 37 ◦C with 5% CO2. The PaCa44 cell line was kindly
provided by Dr. Aldo Scarpa (University of Verona, Verona, Italy) and the MCF7, T47D,
and MDA-MB-231 cell lines were purchased from ATCC (Manassas, VA, USA).
Cancer stem cells (CSCs) were obtained as previously described by us and other
research groups [18–20]. Briefly, adherent MCF7 cells were washed twice in 1× PBS
(Thermo Fisher Scientific, Waltham, MA, USA) and then cultured in stem-specific medium,
i.e., DMEM/F-12 without glucose (US Biological Life Sciences, Salem, MA, USA) supple-
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mented with 1 g/L glucose, B27, 1 µg/mL fungizone, 1% penicillin/streptomycin (all from
Gibco/Life Technologies, USA), 5 µg/mL heparin (Sigma/Merck, St. Louis, MO, USA),
20 ng/mL epidermal growth factor (EGF), and 20 ng/mL fibroblast growth factor (FGF)
(both from PeproTech, London, UK) and cultured in ultra-low-attachment flasks (Sarstedt,
Nümbrecht, Germany).
CD44+/CD24− CSCs were sorted using Becton Dickinson FACSAria Fusion (BD
Biosciences, San Jose, CA, USA). Briefly, to sort tumor cells with CD44-positive and CD24-
negative (CD44+/CD24−) marker expression, MCF7 cells were washed with phosphate-
buffered saline (PBS) and harvested with 0.05% trypsin/0.025% EDTA. Cells were then
subjected to antibody binding, i.e., combinations of fluorochrome-conjugated monoclonal
antibodies against human CD44 (APC) and CD24 (PE) or their respective isotype controls at
the concentration recommended by the manufacturer, and incubated at room temperature
in the dark for 20 min. After that, cells were washed twice with PBS + 1 mM EDTA + P/S +
1% FBS and resuspended in the same buffer at a concentration of 20–30 × 106 cells/mL of
buffer. Anti-human CD44 (APC) and relative isotype were obtained from BioLegend (San
Diego, CA, USA), whereas anti-human CD24 (PE) and relative isotype were obtained from
MACS. Sorted cells were then cultured in the stem-specific medium, as reported above, for
at least one week.
Before hCG treatment, adherent cells were maintained for 16 h in an FBS-free medium;
then, cells were treated with the indicated doses and for the indicated time with hCG by
keeping cells in the medium without FBS.
Bright field cell images were acquired using an inverted microscope (Axio Vert. A1,
Zeiss, Oberkochen, Germany), and the diameters of more than 80 spheres for each set of
conditions of each biological replicate were measured using ImageJ software (ImageJ,
http://rsb.info.nih.gov/ij/, 1997–2008).
2.3. Immunofluorescence Analysis of LHR-Positive Cells
PaCa44 and MCF7 cells were fixed in 4% paraformaldehyde for 8 min and washed
3 times with PBS for 5 min each. To saturate unspecific binding sites, the cells were
incubated for 45 min at RT with a blocking solution containing 5% BSA in PBS. Samples
were then incubated overnight at 4 ◦C with anti-LHR (1:200; Thermo Fisher #8G9A2,
Waltham, MA, USA) primary antibody diluted in blocking solution. After 3 washes with
PBS of 10 min each, cells were incubated for 1 h at RT in the dark with specific secondary
antibody (1 µg/mL) conjugated with Alexa Fluor-488 (Molecular Probes, Eugene, OR,
USA). Samples were mounted in anti-bleaching medium (Dako Fluorescent Mounting
Medium, Agilent Technologies, Santa Clara, CA, USA) and examined by fluorescence
microscope (Axio Vert. A1, Zeiss).
2.4. Immunoblot Analysis
Immunoblot assays were performed, as previously described [21], by analyzing whole-
cell lysate. Membranes were blocked in 5% low-fat milk in TBST (50 mM Tris pH 7.5, 0.9%
NaCl, 0.1% Tween 20) for 1 h at room temperature (RT) and probed overnight at 4 ◦C
with anti-phospho(Ser473)-Akt (1:2000; Cell Signaling #4060, Danvers, MA, USA) and
anti-Akt (1:1000; Cell Signaling #9272). Horseradish-peroxidase-conjugated anti-mouse
(1:10,000; KPL #074-1806) or anti-rabbit IgGs (1:2000; Cell Signaling #7074) were used as
secondary antibodies. The immunocomplexes were visualized by chemiluminescence
using the ChemidocMP imaging system (Bio-Rad Laboratories, Hercules, CA, USA), and
the intensity of the chemiluminescence response was measured by processing the image
using NIH Image J software (http://rsb.info.nih.gov/nih-image/). Ponceau S staining was
used to confirm loading in different lanes.
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2.5. RNA Extraction and qPCR
RNA extraction and real-time quantitative PCR (qPCR) were performed as previously
described [21]. The primers used were LHR forward, 5′-GCTGCGATTAAGACATGCCA-3′,
LHR reverse, 5′-AGAAGGCCACCACATTGAGA-3′; FSHR forward, 5′-GGCCATGCTCA
TCTTCACTG-3′, FSHR reverse, 5′-ATAGAGGAAGGGGTTGGCAC-3′; Androgen Receptor
(AR) forward, 5′-CCCACTTGTGTCAAAAGCGA-3′, AR reverse, 5′-GCAGCTTCCACATGT
GAGAG-3′; Zeb-1 forward, 5′-GTTACCAGGGAGGAGCAGTGAAA-3′, Zeb-1 reverse, 5′-
GACAGCAGTGTCTTGTTGTTGTAGAAA-3′; OCT3/4 forward 5′-GACAGGGGGAGGG
GAGGAGCTAGG-3′, OCT3/4 reverse 5′-CTTCCCTCCAACCAGTTGCCCCAAAC-3′;
Nanog forward 5′-AGTCCCAAAGGCAAACAACCCACTTC-3′, Nanog reverse 5′-TGCTG
GAGGCTGAGGTATTTCTGTCTC-3′; SOX2 forward 5′-GGGAAATGGGAGGGGTGCAAA
AGAGG-3′, SOX2 reverse 5′-TTGCGTGAGTGTGGATGGGATTGGTG-3′; CDH1 forward
5′-GACACCAACGATAATCCTCCGA-3′, CDH1 reverse 5′-GGCACCTGACCCTTGTACGT-
3′; RPLP0 forward 5′-ACATGTTGCTGGCCAATAAGGT-3′, and RPLP0 reverse 5′-CCTAAA
GCCTGGAAAAAGGAGG-3’.
2.6. Cell Proliferation Assay
MCF7, T47D, and MDA-MB-231 cells and CSCs were plated in 96-well cell culture
plates (5 × 103 cells/well) and incubated at 37 ◦C with 5% CO2. For the MCF7, T47D, and
MDA-MB-231 cells, cell viability was measured by crystal violet assay (Merck Millipore,
Burlington, MA, USA) according to the manufacturer’s protocol, and absorbance was
measured by spectrophotometric analysis (A595nm). The crystal violet assay is designed
to work with adherent cells, and when cells die, they detach from the surface of the plate.
Thus, this assay is suitable for in vitro cell proliferation and cell cytotoxicity studies, as
reported in several manufacturer’s sheets. For MCF7 CSCs, viable cells were counted by
trypan blue dye exclusion.
2.7. Statistical Analysis
ANOVA (post hoc Bonferroni) analysis via GraphPad Prism 5 (GraphPad Software, Inc.,
San Diego, CA, USA) or Student’s t-test (two-tailed) was conducted. p-values of <0.05, <0.01,
or <0.001 were considered to indicate significant difference (for details, see figure legends).
3. Results and Discussion
3.1. hCG Stimulates Breast Cancer Cell Proliferation
In order to study the effect of human chorionic gonadotropin (hCG) on breast cancer
cells, we firstly analyzed the expression of the hCG-specific receptor LHR through confocal
microscopy in MCF7 cells in comparison to the control cell line PaCa44, which does
not express LHR due to its origin, i.e., pancreatic ductal adenocarcinoma. Indeed, the
immunofluorescent analysis showed that LHR was not expressed by PaCa44, whereas
MCF7 cells expressed the receptor at high levels in all the cells with a wide presence of
fluorescent spots all over the cell surfaces (Figure 1A). Furthermore, in addition to the
analysis of LHR protein expression, we also analyzed the mRNA expression patterns of
LHR and two other hormone receptors, FSHR and AR, which emerged as useful markers
for the refinement of breast cancer subtype classification [22]. We extended the analysis of
mRNA receptor levels to two other breast cancer cell lines, i.e., T47D and MDA-MB-231.
Our data show that MCF7, T47D, and MDA-MB-231 cells expressed the mRNA of LHR,
FSHR, and AR at high levels in comparison to control cells (PaCa44 cells) (Figure 1B and
Figure S1), thus supporting the use of these cells, particularly MCF7, to perform studies on
the effect of hCG.
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Figure 1. (A) Representative immunofluorescent images of luteinizing hormone receptor (LHR) expression in PaCa44 and
MCF7 cells. Scale bar: 50 µm. (B) mRNA expression levels of LHR, follicle-stimulating hormone receptor (FSHR), and
AR expressed as “–delta delta Ct” values in relation to the housekeeping gene expression levels (RpLp0) in MCF7 cells
relative to the pancreatic ductal adenocarcinoma cell line PaCa44, used as a control. Values are the means (±SD) of three
independent biological eplicates. Statistic l legen : p < 0.001 (***) for MCF7 cell relative to PaCa44 cells.
Based on the observation that fetal bovine serum (FBS), generally used to culture
i vitr cells, c tains the h rmones LH and FSH (as reported in S ction 2), we analyzed
the proliferation of the three breast cancer cell lines cultured and treated with hCG in FBS-
rich and FBS-deprived media. As shown in Figure S2, MCF7, T47D, and MDA-MB-231 cells
cultured and treated for 72 h in an FBS-complete medium with increasing doses of hCG did
not change in terms of their proliferation in comparison to untreated cells grown in the same
culture condition. This analysis was also performed for shorter hCG treatment periods of
24 and 48 h, showing the same effect (data not shown). MCF7, T47D, and MDA-MB-231
cells cultured in an FBS-deprived medium and treated with increasing doses of hCG for 24,
48, a 72 h showed a significa t increment of proliferation (Figure 2A–C). In detail, we
observed that at a concentration of 10 UI/mL, hCG significan ly stimulated MCF7 cells to
proliferate at all thre ti e , ith an increased exten at igher doses. Furthermore, a
60% increase in proliferation occurred in response to both 50 and 100 UI/mL of hCG at 24
and 72 h (Figure 2A). The proliferation of the T47D and MDA-MB-231 cells also significantly
increased after hCG treatment, with a stronger extent at 72 h (Figure 2B,C). Our data show
that, in serum-free conditions, breast cancer cells are stimulated by hCG to proliferate.
Hence, the elevated expression of LHR receptors in these cells supports the hypothesis that
hCG favors cancer cell growth. These in vitro data indicate that the composition of the
medium is critical to evaluating the effect of hCG, and that it is recommendable to use a
serum-free medium to evaluate the hormonal effect.
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Figure 2. Cell proliferation of MCF7 (A), T47D (B), and MDA-MB-231 (C) cultured in FBS-deprived medium and treated
with 0.1, 0.5, 1, 5, 10, 50, or 100 UI/mL human chorionic gonadotropin (hCG) for 24, 48, or 72 h. Histogram legend:
24 h treatment (light gray); 48 h treatment (dark gray); 72 h treatment (black). Values are the means (±SD) of three
independent biological replicates. Statistical legend: p < 0.5 (*), p < 0.01 (**), p < 0.001 (***) for treated cells relative to
untreated cells (control).
3.2. hCG Increases the Phosphorylation of Akt and Regulates the Expression of Hormone Receptors
To confirm that hCG stimulates the LHR down-stream pathway, we analyzed the
phosphorylation level of the kinase Akt, which has been described to be phosphorylated
and then activated after LHR stimulation [23]. In order to analyze modulation of the LHR
down-stream pathway, we chose two hCG concentrations, 1 and 10 UI/mL, at which MCF7
cell proliferation was moderately induced (Figure 2B). Indeed, the immunoblot analysis
showed that both 1 and 10 UI/mL hCG increased the level of the phosphorylated form of
Akt after 20 min of stimulation (Figure 3A). Interestingly, the Akt phosphorylation was
strongly decreased after 30 min, suggesting that the effect of the hormone takes place
within a short range of time. Another evaluation of the effect of hCG was made via analysis
of LHR mRNA levels, the expression of which has been described to be decreased after
LHR stimulation. Indeed, it was previously demonstrated that the activation of LHR brings
about a decrease in its mRNA expression due to the induction of miRNA-122 [24]. In
line with this, our data show that the LHR mRNA level was significantly decreased after
hCG treatments at both 1 and 10 UI/mL for 24 and 48 h (Figure 3B). Furthermore, we also
analyzed the mRNA levels of FSHR and AR and observed that the FSHR mRNA expression
level was decreased, whereas that of AR was increased (Figure 3B), thus opening the way
to further hypotheses about the pleiotropic effect of hCG in breast cancer cells.
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Figure 3. (A) Representative Western blots of phosph - and total-Akt normalized on Ponceau S. The
densitometric analysis is the average of three biological replicates. (B) mRNA expression levels of
LHR, FSHR, and AR relative to the housekeeping gene expression levels (RpLp0) in MCF7 cells
untreated r treate with 1 or 10 UI/mL hCG for 24 or 48 h in a serum-free medium. Values
are the m ans (±SD) of three independent biol gical replicates. Statistical legend: p < 0.5 (*) and
p < 0.001 (***) for treated cells relative to untreated MCF7 cells (control).
3.3. hCG Stimulates Breast Cancer Stem Cell Proliferation and Differentiation
Since it has been described that hCG favors the differentiation of mammary gland
tumor cells [8], we studied the effect of hCG on cancer stem cells (CSCs) derived from
the MCF7 cell line (parental cells). In addition, we also tested hCG’s effect on a subclass
of CSCs with CD44+/CD24− marker expression, which have been shown to have the
highest tumorigenic potential in tumor cell invasion and nude mouse xenograft assays [25].
Firstly, in order to confirm the stem properties of the obtained cells, we characterized
their capacity to form mammospheres and to express stem and epithelial-to-mesenchymal
transition (EMT) markers. Our data show that cells cultured in CSC-specific medium
were able to form floating round-shaped aggregates (Figure 4A), representing a stem
hallmark [18]. Furthermore, both CSCs and CD44+/CD24− CSCs significantly expressed
the stem markers SOX2 and OCT3/4 mRNA at high levels. Interestingly, only CSCs
expressed low levels of the EMT marker CDH1 (this transcribes for E-cadherin, which is
down-regulated in mesenchymal cells) (Figure 4B), in comparison to differentiated MCF7
parental cells, whereas CD44+/CD24− CSCs expressed high levels of CDH1, opening
the way to future analyses of their propensity to perform EMT. In order to analyze the
effect of hCG on CSC proliferation, we treated MCF7 CSCs and CD44+/CD24− CSCs
with three doses of hCG—1, 10, and 100 UI/mL—for 72 h and evaluated cell growth. In
accordance with the data obtained on parental cells (Figure 2), hCG stimulated CSCs and
CD44+/CD24− CSCs to proliferate, with increased extent at 10 and 100 UI/mL (Figure 4C),
further supporting a pro-tumor effect of hCG treatment in this known highly aggressive
subclass of cancer cells.
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gray bar), and CD44+/CD24− CSCs (dark grey bar). mRNA expression levels of SOX2, OCT3/4, and CDH1 relative to the
housekeeping gene expression levels (RpLp0) in MCF7 CSCs (D) and CD44+/CD24− CSCs (E) untreated (white bar) or
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(±SD) of three independent biological replicates. Statistical legend: p < 0.5 (*), p < 0.01 (**), p < 0.001 (***) for treated cells
relative to untreated cells (control).
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Since it has been shown that CSCs may differentiate under specific stimuli in order to
colonize a secondary organ to generate metastases, we also investigated the effect of hCG
on the differentiation of CSCs. To study CSC differentiation, we analyzed whether CSC
sphere size was decreased by hCG treatment, representing a first hallmark of the loss of
stem features. Indeed, there was a strong reduction in sphere size after 100 UI/mL hCG
treatment (Figure S3A), and the sphere area was significantly decreased after treatments
with 1, 10, and 100 UI/mL hCG (Figure S3B). Interestingly, at higher doses of hCG, the cell
sphere size progressively decreased, suggesting a stronger differentiation capacity of hCG
at higher doses. It is noteworthy that cell viability was maintained at a high level (more than
85%) in all the conditions (for details, see Section 2). To confirm these data at the mRNA
level, we analyzed the stem and EMT marker expression in CSCs and CD44+/CD24− CSCs
treated with 1 UI/mL of hCG for 24 h (Figure 4D,E). Our data indicate that CSCs treated
with hCG showed significantly decreased expression of SOX2, by 0.78 fold, in comparison
to untreated cells, whereas OCT3/4 and CDH1 mRNA levels were unchanged (Figure 4D);
this suggests that in these cells, SOX2 may be one of the first actors in the differentiation
process. In CD44+/CD24− CSCs, hCG decreased the expression of both SOX2 and OCT3/4
to a significant extent (Figure 4E).
4. Conclusions
Because different studies that investigated the effect of hCG in cancer cells, including
the breast cancer cell line MCF7, have reported controversial results [26], we hypothesized
that the presence of serum, which generally contains LH and FSH, in the culture medium
may influence cell response to the exogenous administration of hCG. Thus, to shed light
on the effect of this hormone in cancer cells, we analyzed the effect and the role of hCG
treatment on breast cancer cells in serum-free conditions. Overall, our data showed that
hCG stimulates cell proliferation, allowing us to hypothesize that the propensity of breast
cancer cells to express the hormone receptor LHR renders them highly sensitive to hCG
treatment by increasing their proliferative capacity. In addition, we also showed that hCG
is able to increase the differentiation of cancer stem cells, thus potentially rendering them
more able to colonize and invade the primary organ or to metastasize. Thus, our data
suggest that, in order to study the effect of hCG in vitro, it is desirable to culture cells in
the absence of serum in order to avoid interference by the other hormones contained in
it. From a clinical point of view, further studies of the role of hCG in breast cancer may
be particularly important in pregnancy-associated breast cancers. Finally, this study also
offers new perspectives for future research about the effect of hCG, not only in cancer
cells and CSCs, but also on human cells and human stem cells, focusing on infertility and
fertility preservation.
Supplementary Materials: The following are available online at https://www.mdpi.com/2073-440
9/10/2/264/s1, Figure S1: mRNA expression levels of LHR, FSHR, and AR expressed as “–delta delta
Ct” values in relation to the housekeeping gene expression levels (RpLp0) in T47D and MDA-MB-231
cells relative to the pancreatic ductal adenocarcinoma cell line PaCa44, used as a control. Values are
the means (±SD) of three independent biological replicates. Statistical legend: p < 0.001 (***) for
T47D or MDA-MB-231 cells relative to PaCa44 cells, Figure S2: Cell proliferation of MCF7 (A), T47D
(B), and MDA-MB-231 (C) cultured in FBS-complete medium and treated with 0.1, 0.5, 1, 5, 10, 50, or
100 UI/mL hCG for 72 h, Figure S3: Representative images (A) and quantification of the sphere area
of MCF7 CSCs untreated (control) or treated with 100 UI/mL hCG for 48 h (B). Scale bar: 50 mm.
Values are the means (±SD) of three independent biological replicates. Statistical legend: p < 0.5 (*),
p < 0.01 (**), p < 0.001 (***) for treated CSCs relative to untreated MCF7 CSCs (control).
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